LANOXICAPS
LOE ApproachingNDAORALCAPSULE
Approved
Jul 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LANOXICAPS is an oral capsule formulation approved in 1982 as an NDA small-molecule drug by GSK. The generic name and mechanism of action are not publicly disclosed in available data. Specific indications and therapeutic area remain undocumented.
LOE Approaching
Product is approaching loss of exclusivity; commercial teams should anticipate resource reallocation and smaller headcount as brand transitions to legacy status.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring for LANOXICAPS roles. Working on this product offers limited career advancement given its legacy status and approaching LOE. Professionals should view assignments here as consolidation roles or stepping stones to growth-stage assets.
Brand ManagerField Sales Representative
Worked on LANOXICAPS at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.